Edition:
United Kingdom

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

59.88EUR
4:35pm BST
Change (% chg)

€0.04 (+0.07%)
Prev Close
€59.84
Open
€60.34
Day's High
€62.02
Day's Low
€59.80
Volume
1,875,159
Avg. Vol
1,411,387
52-wk High
€72.76
52-wk Low
€58.96

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €39,028.29
Shares Outstanding(Mil.): 554.54
Dividend: 0.62
Yield (%): 0.88

Financials

  FREG.DE Industry Sector
P/E (TTM): 22.53 28.18 33.64
EPS (TTM): 3.12 -- --
ROI: 9.33 6.90 14.27
ROE: 14.09 11.00 15.99

German stocks - Factors to watch on Oct. 19

BERLIN, Oct 19 The following are some of the factors that may move German stocks on Friday:

19 Oct 2018

UPDATE 1-Fresenius Medical cuts 2018 targets, sending shares tumbling

* FMC shares slump 13.7 pct, Fresenius down 8.9 pct (Recasts, adds outlook, analyst, trader comment, changes dateline)

17 Oct 2018

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

01 Oct 2018

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

01 Oct 2018

REFILE-UPDATE 2-Delaware judge says Fresenius can walk away from $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

01 Oct 2018

Judge rules for Fresenius in bid to end $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 A Delaware judge ruled on Monday that German healthcare group Fresenius SE could walk away from its $4.75 billion deal for U.S. drugmaker Akorn Inc and rejected Akorn's claim that the merger agreement had been breached.

01 Oct 2018

Fresenius shares jump on report of win in Akorn ruling

LONDON Shares in German healthcare group Fresenius surged up 9.3 percent on Monday after a Bloomberg report that the firm won a ruling to pull out of a $4.3 billion deal to buy U.S. generic pharmaceuticals company Akorn .

01 Oct 2018

UPDATE 3-Akorn row overshadows Fresenius' generics guidance

* CEO says expect case to be resolved by early 2019 (Adds CEO comments from analyst call)

31 Jul 2018

Fresenius nudges up Kabi earnings guidance

BERLIN, July 31 Fresenius SE nudged up its earnings guidance for its Kabi generics unit on Tuesday as it posted a 3 percent rise in adjusted group net profit in the second quarter.

31 Jul 2018

Cultural mix a hidden weapon in Nestle CEO's activist defense

LONDON Growing up in Germany, Mark Schneider was pushed to become fluent in English by his father, who believed it would give him an edge.

06 Jul 2018

Earnings vs. Estimates